ArticleFrontiers in public health2026
Persistent racial and socioeconomic inequities in mycosis fungoides survival: a population-based study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Racial disparities in mycosis fungoides (MF) have been described historically, but their persistence in the contemporary era of diagnosis and care remains incompletely characterized. To address this gap, we evaluated survival disparities by race and socioeconomic status (SES) and assessed temporal trends in outcomes. To this end, we used the Surveillance, Epidemiology, and End Results (SEER)-22 database (2000-2021) to identify 13,694 patients with MF. Overall survival (OS) was assessed with Kaplan-Meier analyses and multivariable Cox proportional hazards models. Building on these traditional analyses, we also developed registry-based prognostic models using routinely collected variables with internal validation and geographic/registry-based external validation in a non-overlapping SEER registry subset. Across the study population, the overall 1-, 3-, and 5-year OS rates were 96.8%, 90.8%, and 85.8%, respectively. Survival was lower among Black and American Indian/Alaska Native (AI/AN) patients and highest among Asian/Pacific Islander (API) patients (5-year OS: 85.3% White, 82.7% Black, 92.9% API, 82.1% AI/AN). In multivariable adjusted analyses, Black race remained independently associated with higher mortality, whereas API race was associated with better survival. OS improved modestly in the post-2010 period overall, with a statistically significant improvement among White patients, while changes within other racial groups were not statistically significant. Importantly, lower SES independently predicted worse survival, and Black and AI/AN patients were disproportionately represented in lower-income quartiles; a similar SES distribution pattern was also observed in the National Inpatient Sample. In an integrative Cox model, Black or AI/AN race, older age, male sex, advanced stage, and lower SES independently predicted worse survival. Taken together, these findings indicate persistent racial and socioeconomic inequities in MF survival in the contemporary era. Interpretable prognostic models based on routinely collected variables may therefore support individualized risk stratification and inform efforts to improve equity in MF care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.